HIV 치료제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2034년)

HIV Drugs Market - Scope of Report

TMR's report on the global HIV drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global HIV drugs market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global HIV drugs market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the HIV drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global HIV drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global HIV drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global HIV drugs market.

The report delves into the competitive landscape of the global HIV drugs market. Key players operating in the global HIV drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global HIV drugs market profiled in this report.

Key Questions Answered in Global HIV drugs Market Report:

• What is the sales/revenue generated by HIV drugs across all regions during the forecast period?
• What are the opportunities in the global HIV drugs market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

HIV Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global HIV drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global HIV drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global HIV drugs market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global HIV Drugs Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Product Definition
  • 4.1.2. Industry Evolution/Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global HIV Drugs Market Analysis and Forecast, 2020-2034

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Key Product/Brand Analysis
• 5.3. Key Mergers & Acquisitions
• 5.4. COVID-19 Pandemic Impact on Industry

6. Global HIV Drugs Market Analysis and Forecast, by Drug Type

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Drug Type, 2020-2034
  • 6.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • 6.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • 6.3.3. Protease Inhibitors (PIs)
  • 6.3.4. Fusion Inhibitors (FIs)
  • 6.3.5. C-C Chemokine Receptor Type 5 (CCR5)
  • 6.3.6. Integrase Inhibitors
  • 6.3.7. Attachment Inhibitors
  • 6.3.8. Post Attachment Inhibitors
  • 6.3.9. Pharmacokinetic Enhancers
  • 6.3.10. Post-Exposure Prophylaxis (PEP)
  • 6.3.11. Pre-Exposure Prophylaxis (PrEP)
  • 6.3.12. Others (Combination HIV Medications, etc.)
• 6.4. Market Attractiveness Analysis, by Drug Type

7. Global HIV Drugs Market Analysis and Forecast, by Distribution Channel

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Distribution Channel, 2020-2034
  • 7.3.1. Hospital Pharmacies
  • 7.3.2. Retail Pharmacies
  • 7.3.3. Online Pharmacies
• 7.4. Market Attractiveness Analysis, by Distribution Channel

8. Global HIV Drugs Market Analysis and Forecast, by Region

• 8.1. Key Findings
• 8.2. Market Value Forecast, by Region, 2020-2034
  • 8.2.1. North America
  • 8.2.2. Europe
  • 8.2.3. Asia Pacific
  • 8.2.4. Latin America
  • 8.2.5. Middle East & Africa
• 8.3. Market Attractiveness Analysis, by Region

9. North America HIV Drugs Market Analysis and Forecast

• 9.1. Introduction
• 9.2. Key Findings
• 9.3. Market Value Forecast, by Drug Type, 2020-2034
  • 9.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • 9.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • 9.3.3. Protease Inhibitors (PIs)
  • 9.3.4. Fusion Inhibitors (FIs)
  • 9.3.5. C-C Chemokine Receptor Type 5 (CCR5)
  • 9.3.6. Integrase Inhibitors
  • 9.3.7. Attachment Inhibitors
  • 9.3.8. Post Attachment Inhibitors
  • 9.3.9. Pharmacokinetic Enhancers
  • 9.3.10. Post-Exposure Prophylaxis (PEP)
  • 9.3.11. Pre-Exposure Prophylaxis (PrEP)
  • 9.3.12. Others (Combination HIV Medications, etc.)
• 9.4. Market Value Forecast, by Distribution Channel, 2020-2034
  • 9.4.1. Hospital Pharmacies
  • 9.4.2. Retail Pharmacies
  • 9.4.3. Online Pharmacies
• 9.5. Market Value Forecast, by Country, 2020-2034
  • 9.5.1. U.S.
  • 9.5.2. Canada
• 9.6. Market Attractiveness Analysis
  • 9.6.1. By Drug Type
  • 9.6.2. By Distribution Channel
  • 9.6.3. By Country

10. Europe HIV Drugs Market Analysis and Forecast

• 10.1. Introduction
• 10.2. Key Findings
• 10.3. Market Value Forecast, by Drug Type, 2020-2034
  • 10.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • 10.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • 10.3.3. Protease Inhibitors (PIs)
  • 10.3.4. Fusion Inhibitors (FIs)
  • 10.3.5. C-C Chemokine Receptor Type 5 (CCR5)
  • 10.3.6. Integrase Inhibitors
  • 10.3.7. Attachment Inhibitors
  • 10.3.8. Post Attachment Inhibitors
  • 10.3.9. Pharmacokinetic Enhancers
  • 10.3.10. Post-Exposure Prophylaxis (PEP)
  • 10.3.11. Pre-Exposure Prophylaxis (PrEP)
  • 10.3.12. Others (Combination HIV Medications, etc.)
• 10.4. Market Value Forecast, by Distribution Channel, 2020-2034
  • 10.4.1. Hospital Pharmacies
  • 10.4.2. Retail Pharmacies
  • 10.4.3. Online Pharmacies
• 10.5. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 10.5.1. Germany
  • 10.5.2. U.K.
  • 10.5.3. France
  • 10.5.4. Italy
  • 10.5.5. Spain
  • 10.5.6. Rest of Europe
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Drug Type
  • 10.6.2. By Distribution Channel
  • 10.6.3. By Country/Sub-region

11. Asia Pacific HIV Drugs Market Analysis and Forecast

• 11.1. Introduction
• 11.2. Key Findings
• 11.3. Market Value Forecast, by Drug Type, 2020-2034
  • 11.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • 11.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • 11.3.3. Protease Inhibitors (PIs)
  • 11.3.4. Fusion Inhibitors (FIs)
  • 11.3.5. C-C Chemokine Receptor Type 5 (CCR5)
  • 11.3.6. Integrase Inhibitors
  • 11.3.7. Attachment Inhibitors
  • 11.3.8. Post Attachment Inhibitors
  • 11.3.9. Pharmacokinetic Enhancers
  • 11.3.10. Post-Exposure Prophylaxis (PEP)
  • 11.3.11. Pre-Exposure Prophylaxis (PrEP)
  • 11.3.12. Others (Combination HIV Medications, etc.)
• 11.4. Market Value Forecast, by Distribution Channel, 2020-2034
  • 11.4.1. Hospital Pharmacies
  • 11.4.2. Retail Pharmacies
  • 11.4.3. Online Pharmacies
• 11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 11.5.1. China
  • 11.5.2. Japan
  • 11.5.3. India
  • 11.5.4. Australia & New Zealand
  • 11.5.5. Rest of Asia Pacific
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Drug Type
  • 11.6.2. By Distribution Channel
  • 11.6.3. By Country/Sub-region

12. Latin America HIV Drugs Market Analysis and Forecast

• 12.1. Introduction
• 12.2. Key Findings
• 12.3. Market Value Forecast, by Drug Type, 2020-2034
  • 12.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • 12.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • 12.3.3. Protease Inhibitors (PIs)
  • 12.3.4. Fusion Inhibitors (FIs)
  • 12.3.5. C-C Chemokine Receptor Type 5 (CCR5)
  • 12.3.6. Integrase Inhibitors
  • 12.3.7. Attachment Inhibitors
  • 12.3.8. Post Attachment Inhibitors
  • 12.3.9. Pharmacokinetic Enhancers
  • 12.3.10. Post-Exposure Prophylaxis (PEP)
  • 12.3.11. Pre-Exposure Prophylaxis (PrEP)
  • 12.3.12. Others (Combination HIV Medications, etc.)
• 12.4. Market Value Forecast, by Distribution Channel, 2020-2034
  • 12.4.1. Hospital Pharmacies
  • 12.4.2. Retail Pharmacies
  • 12.4.3. Online Pharmacies
• 12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 12.5.1. Brazil
  • 12.5.2. Mexico
  • 12.5.3. Rest of Latin America
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Drug Type
  • 12.6.2. By Distribution Channel
  • 12.6.3. By Country/Sub-region

13. Middle East & Africa HIV Drugs Market Analysis and Forecast

• 13.1. Introduction
• 13.2. Key Findings
• 13.3. Market Value Forecast, by Drug Type, 2020-2034
  • 13.3.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • 13.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • 13.3.3. Protease Inhibitors (PIs)
  • 13.3.4. Fusion Inhibitors (FIs)
  • 13.3.5. C-C Chemokine Receptor Type 5 (CCR5)
  • 13.3.6. Integrase Inhibitors
  • 13.3.7. Attachment Inhibitors
  • 13.3.8. Post Attachment Inhibitors
  • 13.3.9. Pharmacokinetic Enhancers
  • 13.3.10. Post-Exposure Prophylaxis (PEP)
  • 13.3.11. Pre-Exposure Prophylaxis (PrEP)
  • 13.3.12. Others (Combination HIV Medications, etc.)
• 13.4. Market Value Forecast, by Distribution Channel, 2020-2034
  • 13.4.1. Hospital Pharmacies
  • 13.4.2. Retail Pharmacies
  • 13.4.3. Online Pharmacies
• 13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 13.5.1. GCC Countries
  • 13.5.2. South Africa
  • 13.5.3. Rest of Middle East & Africa
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Drug Type
  • 13.6.2. By Distribution Channel
  • 13.6.3. By Country/Sub-region

14. Competition Landscape

• 14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
• 14.2. Market Share Analysis, by Company (2023)
• 14.3. Company Profiles
  • 14.3.1. Teva Pharmaceutical Industries Ltd.
    • 14.3.1.1. Company Overview
    • 14.3.1.2. Product Portfolio
    • 14.3.1.3. SWOT Analysis
    • 14.3.1.4. Financial Overview
    • 14.3.1.5. Strategic Overview
  • 14.3.2. Boehringer Ingelheim International GmbH
    • 14.3.2.1. Company Overview
    • 14.3.2.2. Product Portfolio
    • 14.3.2.3. SWOT Analysis
    • 14.3.2.4. Financial Overview
    • 14.3.2.5. Strategic Overview
  • 14.3.3. Johnson & Johnson
    • 14.3.3.1. Company Overview
    • 14.3.3.2. Product Portfolio
    • 14.3.3.3. SWOT Analysis
    • 14.3.3.4. Financial Overview
    • 14.3.3.5. Strategic Overview
  • 14.3.4. F. Hoffmann-La Roche Ltd.
    • 14.3.4.1. Company Overview
    • 14.3.4.2. Product Portfolio
    • 14.3.4.3. SWOT Analysis
    • 14.3.4.4. Financial Overview
    • 14.3.4.5. Strategic Overview
  • 14.3.5. Gilead Sciences, Inc.
    • 14.3.5.1. Company Overview
    • 14.3.5.2. Product Portfolio
    • 14.3.5.3. SWOT Analysis
    • 14.3.5.4. Financial Overview
    • 14.3.5.5. Strategic Overview
  • 14.3.6. GSK plc
    • 14.3.6.1. Company Overview
    • 14.3.6.2. Product Portfolio
    • 14.3.6.3. SWOT Analysis
    • 14.3.6.4. Financial Overview
    • 14.3.6.5. Strategic Overview
  • 14.3.7. AbbVie Inc.
    • 14.3.7.1. Company Overview
    • 14.3.7.2. Product Portfolio
    • 14.3.7.3. SWOT Analysis
    • 14.3.7.4. Financial Overview
    • 14.3.7.5. Strategic Overview
  • 14.3.8. Cipla Limited
    • 14.3.8.1. Company Overview
    • 14.3.8.2. Product Portfolio
    • 14.3.8.3. SWOT Analysis
    • 14.3.8.4. Financial Overview
    • 14.3.8.5. Strategic Overview
  • 14.3.9. Bristol-Myers Squibb Company
    • 14.3.9.1. Company Overview
    • 14.3.9.2. Product Portfolio
    • 14.3.9.3. SWOT Analysis
    • 14.3.9.4. Financial Overview
    • 14.3.9.5. Strategic Overview
  • 14.3.10. Merck & Co., Inc.
    • 14.3.10.1. Company Overview
    • 14.3.10.2. Product Portfolio
    • 14.3.10.3. SWOT Analysis
    • 14.3.10.4. Financial Overview
    • 14.3.10.5. Strategic Overview